Uploaded August 2026 | Updated September 2026, 2 weeks ago

---

A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer. #skincare #cancer #vaccine #news #usa #health

The trial met its main goal as the vaccine, combined with Merck’s immune drug Keytruda, prevented the cancer’s return after it was surgically removed more often than the immunotherapy alone.

The study provides the strongest evidence yet that the mRNA technology will have a successful second act, and the companies will discuss filing for approval with regulators and plan to present the data at an upcoming medical meeting.

Read more: bloomberg.com/news/articles/2026-08-19/moderna-merck-mrna-shot-helped-cut-melanoma-recurrence-in-big-trial

----------
Like this video? Subscribe youtube.com/@Bloomberg-News

Bloomberg News is the first word in business news. Visit bloomberg.com for the latest on global business, markets and more.
Get unlimited access to Bloomberg.com for $1.99/month for the first 3 months: bloomberg.com/subscriptions?in_source=YoutubeOriginals

Bloomberg on YouTube:
youtube.com/@business
youtube.com/@markets
youtube.com/@BloombergTechnology
youtube.com/@BloombergPodcasts

Connect with us on social:
instagram.com/bloombergbusiness
linkedin.com/company/bloomberg-news
tiktok.com/@bloombergbusiness
facebook.com/bloombergbusiness